ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float

ZyVersa Therapeutics, Inc.

Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.
Approved issuance of up to 1,637,000 shares upon exercise of November 2024 warrants.
Approved issuance of up to 2,105,265 shares upon exercise of March 2025 warrants.
Combined potential dilution (3.84M shares) exceeds current outstanding of 3.62M shares.
All five proposals including director re-election and auditor ratification passed at June 11 annual meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.